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Abstract 26 
The endocannabinoid system (ECS) has gained much attention as a new potential 27 
pharmacotherapeutic target in various neurodegenerative diseases, including Alzheimer's 28 
disease (AD). However, the association between CB1 alterations and the development of AD 29 
neuropathology is unclear and often contradictory. In this study, brain CB1 mRNA and CB1 30 
protein levels were analysed in 3×Tg-AD mice and compared to wild-type littermates at 2, 6 31 
and 12 months of age, using in-situ hybridization and immunohistochemistry, respectively. 32 
Semiquantitative analysis of CB1 expression focused on the prefrontal cortex (PFC), 33 
prelimbic cortex (PrL), dorsal hippocampus (DH), basolateral amygdala complex (BLA) and 34 
ventral hippocampus (VH), all areas with high CB1 densities that are strongly affected by 35 
neuropathology in 3×Tg-AD mice. At 2 months of age, there was no change in CB1 mRNA 36 
and protein levels in 3×Tg-AD mice compared to Non-Tg mice in all brain areas analyzed. 37 
However, at 6 and 12 months of age, CB1 mRNA levels were significantly higher in PFC, 38 
DH, BLA and lower in VH in 3×Tg-AD mice compared to wild-type littermates. CB1 39 
immunohistochemistry revealed that CB1 protein expression was unchanged in 3×Tg-AD at 2 40 
and 6 months of age, while a significant decrease in CB1 receptor immunoreactivity was 41 
detected in the BLA and DH of 12-month-old 3×Tg-AD mice, with no sign of alteration in 42 
other brain areas. The altered CB1 levels appear, rather, to be age-and/or pathology-43 
dependent, indicating an involvement of the ECS in AD pathology and supporting the ECS as 44 
a potential novel therapeutic target for treatment of AD. 45 
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Introduction  51 
Alzheimer’s disease (AD) is progressive, degenerative and irreversible neurological disorder 52 
that causes deterioration of memory, judgment and reasoning in the elderly. AD is 53 
characterized by accumulation of extracellular insoluble plaques, intracellular neurofibrillary 54 
tangles (NFTs) in the brain and selective synaptic and neuronal loss. Extracellular plaques 55 
consist of amyloid-β (Aβ) protein and NFTs are composed of hyperphosphorylated tau protein 56 
[1]. Although Aβ plaques and NFTs pathology are prominent, other pathological alterations in 57 
neurotransmitter systems and concomitant changes in synthetic enzymes and associated 58 
receptors are also an important feature of AD. For example, cholinergic and glutamatergic 59 
neurotransmitter systems are known to be affected by AD [2].   60 
The endocannabinoid system (ECS) has gained much attention as a new potential 61 
pharmacotherapeutic target in various neurodegenerative diseases including AD. The CB1-62 
type cannabinoid receptor (CB1) is the most abundant G protein–coupled receptor expressed 63 
in the central nervous system (CNS) and through the activation of CB1 receptors in the CNS, 64 
the ECS exerts important functions such as retrograde inhibition of neurotransmitter release, 65 
control of neuronal excitability, and regulation of various forms of synaptic plasticity [3]. 66 
Aberrant patterns of brain CB1 receptor expression and densities have been observed 67 
postmortem in patients suffering from AD and in animal models of AD. However, these 68 
observations are sparse and often contradictory [4-8], so the relationship between alterations 69 
in CB1 expression and the development of AD neuropathology is still unclear.  70 
Oddo and his colleagues developed a triple transgenic mouse model of AD (3×Tg-AD) 71 
harbouring three mutant human genes PS1M146V, APPSwe, and TauP301L [9]. This model mimics 72 
critical aspects of AD neuropathology observed in the human AD patients [10, 11]: it 73 
progressively develops both plaques and tangles in AD relevant brain regions (mainly cortex, 74 
hippocampus and amygdala); it exhibits early deficits in synaptic plasticity, including long-75 
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term potentiation; it shows selective loss of α7 neuronal nicotinic acetylcholine receptors [9, 76 
12], severe deficits in glutamatergic neurotransmission and altered mitochondrial functions in 77 
hippocampus and cortex [13]. 78 
The aim of the present study was to evaluate whether brain CB1 expression is altered in 79 
3×Tg-AD mice in comparison with wild type littermates (Non-Tg). Moreover, to investigate 80 
whether the temporal and regional patterns of such possible alterations might overlap with 81 
those of Aβ and tau pathology in this AD model, brain CB1 expression was analysed at 82 
different ages [9]. As a consequence, by studying the temporal expression of CB1 in the wild 83 
type littermates, our study has also allowed us to analyse the impact of aging on CB1 levels. 84 
Our analyses were conducted on both CB1 mRNA and CB1 protein levels in 3×Tg-AD and 85 
wild-type mice at 2, 6 and 12 months of age, by in situ hybridization and 86 
immunohistochemistry/immunofluorescence, respectively, followed by the semi-quantitative 87 
analysis of the respective signals obtained in prefrontal cortex (PFC), prelimbic cortex (PrL), 88 
dorsal hippocampus (DH), basolateral amygdala complex (BLA) and ventral hippocampus 89 
(VH), all areas strongly affected by the neuropathology and characterized by high CB1 90 
densities. 91 
 92 
  93 
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Materials and Methods 94 
Animals 95 
Male 3×Tg-AD and Non-Tg mice aged 2-, 6-, and 12-months old were used in this study. The 96 
3×Tg-AD mice harboring PS1M146V, APPSwe, and TauP301L transgenes were genetically 97 
engineered by LaFerla and colleagues at the Department of Neurobiology and Behavior, 98 
University of California, Irvine [9]. Colonies of 3×Tg-AD mice and Non-Tg littermates were 99 
established at the vivarium of the Puglia and Basilicata Experimental Zooprophylactic 100 
Institute (Foggia, Italy). The 3×Tg-AD mice background strain is C57BL6/129SvJ hybrid and 101 
genotypes were confirmed from tail biopsy, according to the procedures described previously 102 
[9, 14]. The housing conditions were controlled (temperature 22°C, light from 07:00 –19:00, 103 
humidity 50%–60%), and fresh food and water were freely available. 104 
 105 
In situ hybridization 106 
In situ hybridization was performed on coronal sections of brains using a 35S-labeled RNA 107 
probe complementary to rat CB1 mRNA. Riboprobes in antisense and sense orientation were 108 
generated from linearized vector constructs (520 bp, a kind gift of Dr. Jin Fu, Xiamen 109 
University) by in vitro transcription using the appropriate RNA polymerases [15].  110 
Mice (n = 5 per group) were euthanized by decapitation; their brains were rapidly removed, 111 
snap frozen in 2-methylbutane (-50°C) and stored at -80°C. Brain sections (20 μm) were cut 112 
on a cryostat (-20°C) and thaw-mounted on RNAse-free positively charged slides to be 113 
hybridized at 60°C for 16 h in a buffer containing [35S]cRNA (45,000 dpm ml-1), 10% dextran 114 
sulfate, 50% formamide, 1× Denhardt’s solution, 100 µgml-1 denatured salmon sperm DNA, 115 
0.15 mg ml-1  tRNA and 40 mM dithiothreitol. After hybridization, the sections were exposed 116 
to Kodak Biomax film (Sigma-Aldrich) for 3 days. Autoradiography films were first scanned 117 
(Epson perfection 3200 PHOTO) at high resolution (900 dpi). Optical densities were 118 
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converted to radioactivity measurements (μCi) by densitometric analysis of 14C-microscale 119 
standards that were used to create a calibration curve.  120 
 121 
Immunohistochemistry and immunofluorescence 122 
Mice (n = 3 per group) were intra-cardioventricularly perfused with saline followed by 123 
fixation solution (4% paraformaldehyde in 0.1 M phosphate buffer, PB, pH 7.4) at a flow rate 124 
of 36 ml min-1. Then brains were fixed for 48 hours in 4% paraformaldehyde. Free-floating 125 
coronal sections of 50 µm thickness were obtained using a vibratome slicing system (microM, 126 
Walldorf, Germany) and stored at 4°C in 0.02% sodium azide in phosphate buffered (PB). 127 
The endogenous peroxidase activity was quenched for 30 minutes in 0.3% H2O2. The brain 128 
sections were blocked with 10% normal goat serum/PBS with 0.3% Triton X-100 and then 129 
incubated with CB1 2825.3 antiserum  (C-terminus residues 461–473, generously provided by 130 
Dr. Maurice Elphick, Queen Mary College) (1:1500 dilution) for overnight at 4°C [16]. 131 
Evidence of the selectivity of this antiserum in revealing CB1 expression in the rat nervous 132 
system has been previously obtained by pre-absorption tests with the CB1 C-terminal peptide 133 
antigen and by Western blotting, which reveals a band in rat brain homogenates (~53 kDa) 134 
consistent with the expected molecular mass for CB1 [16, 17]. Furthermore, the selectivity of 135 
the antiserum for CB1 has been previously confirmed by analysis of brain tissue and dorsal 136 
root ganglia from CB1-knockout mice [17, 18]. After removing the primary antiserum in 137 
excess, sections were incubated with secondary antibody (Biotin-SP-conjugated fragment 138 
donkey anti rabbit IgG) for 1 h at room temperature. After washing excess of antibody, 139 
sections were treated with avidin–biotin–peroxidase complex (ABC, 1:200 dilution, Vector 140 
Laboratories) and then developed with diaminobenzidine (DAB) substrate using the avidin-141 
biotin horseradish peroxidase system (Vector Laboratories).  142 
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For immunofluorescence staining, free floating coronal brain sections of 30 µm thickness 143 
were obtained using a cryostat (Microm HM550, Thermo scientific) and stored at 4°C in 144 
0.02% sodium azide in PB. The brain sections were treated with 90% of formic acid for 7 min 145 
followed by PB washes. Then the brain sections were blocked in a solution containing 5% 146 
normal goat serum and 0.3% Triton X-100 in PB and then incubated with both CB1 2825.3 147 
antiserum (1:1500 dilution) and Aβ monoclonal antibody (6E10, Covance, 1:1500 dilution) 148 
for 16 h at 4°C. After removing primary antibodies, sections were incubated with both 149 
secondary antibodies Alexa Fluor 555 donkey anti-rabbit IgG (1:250 dilution) and Alexa 150 
Fluor 488 goat anti-mouse IgG (1:250 dilution) for 1 h and 30 min at room temperature. All 151 
washes after this step were carried out in dark. After washing excess of antibodies, sections 152 
were treated with Hoechst, Sigma (1:5000 dilution). After washing excess Hoechst with PB, 153 
brain slices were mounted on slides. Furthermore, to confirm the background staining level, 154 
an immunofluorescent staining for CB1 was also carried out without the primary antibody.  155 
All immunohistochemically-stained sections were viewed using a Nikon 80i Eclipse 156 
microscope equipped with a DS-U1 digital camera, and NIS-elements BR software (Nikon, 157 
Tokyo, Japan). Immunofluorescent slices were observed under the confocal microscope 158 
Olimpus FV-1000.  159 
Semiquantitative analyses of the autoradiographic signal of hybridized CB1 mRNA and of 160 
CB1 DAB-immunostaining or immunofluorescence were performed using freeware software 161 
from the National Institutes of Health (Scion Image software) and were expressed as optical 162 
densities.  163 
 164 
Statistical analysis 165 
The optical densities obtained by the semiquantitative analyses were analyzed by two way 166 
analysis of variance (ANOVA), with genotype and age as variables. Tukey’s honestly 167 
8 
 
significant difference test was used for multiple post hoc comparisons. The correlation 168 
analysis between Aβ and CB1 protein levels was performed on the respective optical densities 169 
measured on double immunofluorescent slices and expressed as percentage of those measured 170 
in Non-Tg mice, by using the Pearson correlation test. Statistical significance threshold was 171 
set at p<0.05.  172 
173 
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Results 174 
CB1 mRNA expression  175 
Representative images of CB1 mRNA distribution in the mouse brain is shown in Fig. 1A and 176 
quantitative analysis of CB1 mRNA expression in PFC, PrL, DH, VH and BLA is shown in 177 
Fig 1B-F. The results from ANOVA revealed an overall effect of genotype [F(genotype)1,122 = 178 
31.992, p < 0.001], age [F(age)2,122 = 16.177, p < 0.001] and genotype u age interaction [F(age x 179 
genotype)2,122 = 4.288, p < 0.05] on CB1 mRNA expression in PFC (Fig. 1B). Post hoc 180 
comparisons revealed that CB1 mRNA expression was significantly higher in 3×Tg-AD mice 181 
compared to Non-Tg mice at 6 months (+56%, p<0.05) and 12 months (+15%, p<0.05) of 182 
age. Different results were obtained for PrL, where a significant overall effect of age was 183 
observed [F(age)2,113 = 18.212, p < 0.001], with no significant overall effect of genotype 184 
[F(genotype)1,113 = 1.161, n.s.] and genotype by age interaction [F(age x genotype)2,113 = 0.871, n.s.] 185 
(Fig. 1C). ANOVA analysis of CB1 mRNA expression in DH and VH demonstrated a 186 
significant overall effect of age, genotype and age by genotype interaction [DH: F(age)2,151 = 187 
81.052, p < 0.001; F(age x genotype)2,151 = 3.166, p < 0.05; F(genotype)1,151 = 19.079, p < 0.001; VH: 188 
F(age)2,182 = 10.431, p < 0.001; F(age x genotype)2,182 = 6.987, p < 0.001; F(genotype)1,182 = 10.116, p < 189 
0.01]. Interestingly, post hoc comparisons revealed a clear dissociation between the dorsal 190 
and ventral hippocampus (Fig. 1D and E, respectively). In particular, the former showed a 191 
significantly higher expression of CB1 mRNA in the 3×Tg-AD mice compared to Non-Tg 192 
mice both at 6 months (+29%, p<0.05) and 12 months (+33%, p<0.05) of age, while in the 193 
latter there was a significant decrease in CB1 mRNA expression in the transgenic mice 194 
compared to the control group (-40% and -35%, respectively at 6 and 12 months of age; 195 
p<0.05). Statistical analysis of CB1 mRNA expression in the BLA revealed a significant 196 
overall effect of age [F(age)2,160 = 14.888, p < 0.001], genotype [F(genotype)1,160 = 31.774, p < 197 
0.001] and age by genotype interaction [F(age x genotype)2,160 = 8.916, p < 0.001] (Fig. 1F). Post 198 
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hoc comparisons revealed that CB1 mRNA expression was significantly higher in 3×Tg-AD 199 
mice compared to Non-Tg mice at 6 months (+78%, p<0.05) and 12 months (+49%, p<0.05) 200 
of age.  201 
 202 
CB1 protein expression  203 
Representative microphotographs of CB1 immunostaining are shown in Fig. 2A. Fig. 2B-F 204 
shows the semiquantitative analysis of CB1 protein expression in the PFC, PrL, DH, VH and 205 
BLA. The results from ANOVA revealed an overall effect of genotype [F(genotype)1,314 = 206 
12.687, p < 0.001] and age [F(age)2,314 = 59.579, p < 0.001] in DH, with no significant overall 207 
effect of genotype u age interaction [F(age x genotype)2,314 = 0.345, n.s.] on CB1 protein 208 
expression (Fig. 2D). Post hoc comparisons revealed that CB1 protein levels were 209 
significantly lower in 3×Tg-AD mice compared to Non-Tg mice at 12 months of age (-20%, 210 
p<0.05) and that, in within-genotype comparisons, both groups of mice at 12 months of age 211 
showed significantly lower CB1 protein levels compared to 2- and 6-month old mice. 212 
For the BLA, ANOVA showed an overall effect of age [F(age)2,67 = 6.735, p < 0.01], with no 213 
significant overall effect of genotype [F(genotype)1,67 = 2.736, n.s.] and significant genotype u 214 
age interaction [F(age x genotype)2,67 = 3.279, p < 0.05] on CB1 protein expression (Fig. 2F). 215 
Interestingly, at 12 months of age 3×Tg-AD mice showed (i) lower CB1 protein expression 216 
compared to age-matched Non-Tg mice (-42%), and (ii) significantly lower CB1 protein 217 
levels compared to 2-month-old (-48%, p<0.05) and 6-month-old (-47%, p<0.05) transgenic 218 
mice.Finally, no significant difference was found between genotypes at 2, 6 and 12 months of 219 
age in PFC, PrL and VH (Fig. 2B, C and E). 220 
Lowered CB1 protein expression in DH and BLA were further confirmed by 221 
immunofluorescent staining (Fig.3 A, B lower panel). At 12 months of age, 3×Tg-AD mice 222 
showed lower CB1 protein levels in DH (-22%, p<0.05) and BLA (-48 %, p<0.05) compared 223 
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to Non-Tg mice (Fig.3 C, D). Moreover, by performing a double immunofluorescence for 224 
CB1 and Aβ (Fig.3 E, F), we could semiquantitatively measure both protein levels and find an 225 
inverse correlation between the decline of CB1 receptor expression and the build up of Aβ 226 
pathology in both the DH (Fig.3 G, DH: ρ= -0.7599, p<0.0001) and the BLA (Fig.3 H, BLA: 227 
ρ= -0.5052, p<0.001, Pearson Correlation test).    228 
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Discussion 229 
In this study the general pattern of CB1 mRNA expression and of CB1 protein distribution 230 
throughout the mouse brain revealed similarity with previous reports [16, 19, 20]. 231 
Furthermore, this study has revealed for the first time that CB1 mRNA and CB1 protein 232 
expression in 3×Tg-AD mice is altered in brain areas particularly involved in learning and 233 
memory processes and where the impact of AD neuropathology is more prominent. More 234 
specifically, a significant increase of CB1 mRNA levels in PFC, DH, BLA and a reduction in 235 
VH were found in 3×Tg-AD mice compared to Non-Tg mice at 6 and 12 months of age. Such 236 
differences were found to be opposite for CB1 protein levels in the DH and BLA, where CB1 237 
protein levels were lower in 12-month-old 3×Tg-AD mice compared to their age-matched 238 
Non-Tg mice. No differences between genotypes were found in the brains of 2-month-old 239 
mice. 240 
Furthermore, the comparisons within mice from the same genotype at different ages revealed 241 
significant effects of aging on both CB1 mRNA and CB1 protein levels in several brain 242 
regions. In particular, we observed an age-dependent increase of CB1 mRNA levels in most 243 
areas for both genotypes (except BLA for Non-Tg mice and VH for 3×Tg-AD mice), while a 244 
decrease of CB1 protein expression was detected in two brain areas of aged mice (the DH for 245 
both genotypes and the BLA for 3×Tg-AD mice) as compared to 2- and 6-months-old mice of 246 
the respective genotype.  247 
In this study, the correlation between CB1 mRNA and protein levels observed was not direct. 248 
This observation is not surprising, as it was previously demonstrated that in general mRNA 249 
levels do not necessarily predict the respective protein levels [21]. Moreover, the discrepant 250 
results obtained here are complex to interpret considering also that CB1 receptors are 251 
expressed mostly on synaptic terminals whilst CB1 mRNA is synthesized mostly in the cell 252 
body. For example, CB1 receptors are abundantly expressed on GABAergic interneurons of 253 
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several brain areas that receive also the nerve terminals expressing CB1 protein from other 254 
structures. In this case the CB1 protein levels will result more abundant that the respective 255 
CB1 mRNA level. Conversely, other sites contain only CB1 expressing terminals with no cell 256 
body expressing CB1 mRNA. Therefore, in these areas not necessarily CB1 protein levels 257 
correspond to CB1 mRNA levels. However, the most obvious hypothesis arising from our 258 
results is that this discrepancy might be due to modifications at translational and/or post-259 
translational levels, occurring at the three different ages considered.  260 
Two months of age in our murine AD-model corresponds to a pre-pathologic phase 261 
characterized by the absence of any Aβ and tau pathological expression [9]. The lack of 262 
differences in CB1 expression between genotypes at this age suggests that 3×Tg-AD mice do 263 
not have inborn altered CB1 expression in the brain regions analysed. Therefore, we speculate 264 
that the altered pattern of CB1 expression found at older ages in their brains can be interpreted 265 
as age- and/or pathology-dependent. In accordance with this hypothesis, an extensive set of 266 
age-related and pathology-related alterations are described in our murine model (see table 1).  267 
At 6 months of age, extracellular Aβ deposits first become apparent in the frontal cortex of 268 
3×Tg-AD mice, while intracellular Aβ immunoreactivity starts to build-up in hippocampus, 269 
cortex and amygdala [9, 22]. At 12 months of age extracellular Aβ deposits are readily 270 
evident in frontal cortex, amygdala, DH and VH; the immunoreactivity for 271 
hyperphosphorylated tau starts to be evident in CA1 neurons of hippocampus, particularly at 272 
the somatodendritic level of pyramidal neurons (progressing later to involve cortical 273 
structures) [9, 14]. 274 
From our results, alterations of CB1 mRNA but not protein levels appear at 6 months of age, 275 
when the AD neuropathology seems to impact on CB1 expression first at transcriptional 276 
levels. Alterations in CB1 expression become more evident at 12 months of age, when they 277 
involve also the protein levels in the BLA and DH, remaining unaltered in the other areas.  278 
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Interestingly, the temporal pattern of the changes of CB1 protein expression observed in our 279 
study seemed to correlate with the temporal pattern of the development of Aβ pathology, at 280 
least in the two brain areas analysed, namely the DH and the BLA. Previous studies 281 
corroborate our finding that CB1 receptors in cortex are unchanged [4, 8] and lowered in DH 282 
[5, 7] in AD. However, some reports showed that CB1 levels are altered in cortex [23, 24] and 283 
unaltered in DH of AD patients [4, 6, 8]. These discrepancies might be due to different 284 
disease models used in each study. Until now, much emphasis has been given to the role of 285 
the ECS in cortex and hippocampus in AD pathology, while leaving the BLA poorly 286 
investigated, in spite of its well-known role in learning, its involvement in AD 287 
neuropathology and its quite high expression of CB1 receptors.  288 
Age-related changes of CB1 mRNA expression in the rodent brain have been already reported 289 
in the literature, although data are still sparse and in some cases discrepant from our results. In 290 
particular, CB1 mRNA was observed to increase steadily throughout neuronal development of 291 
rats and mice until animals reach 2 months of age [25, 26]. Conversely, a decrease of CB1 292 
mRNA has been described in hippocampus and BLA, with no change in cortex, when rats are 293 
24-months-old [27]. These discrepancies with our results might be due to different species 294 
used in these studies.  295 
CB1 receptors play important roles in neuroprotection and the enhancement of 296 
endocannabinoid tone is now considered an attractive therapeutic approach to treat AD. It has 297 
been demonstrated, indeed, that the enhancement of brain endocannabinoid tone is able to 298 
reverse memory impairment and neurotoxic effects triggered by soluble Aβ in murine models 299 
of AD [28]. The neuroprotective function of cannabinoid system is thought to occur through 300 
variety of mechanisms. For example, through CB1 receptor activation anandamide was 301 
recently shown to positively regulate Notch-1 pathway, which plays a key role in 302 
neurogenesis, long term memory and neuronal development, and thus restore AD 303 
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neurodegeneration and memory impairments [29]. Moreover, ECS was also demonstrated to 304 
be involved in clearing Aβ from the blood brain barrier, as demonstrated in vitro by 305 
Bachmeier et through the incubation with cannabinoid receptor agonist or inhibitors of 306 
endocannabinoid-degrading enzymes [30]. Based on our results, we speculate that increasing 307 
the endocannabinoid tone or hyperactivating CB1 receptors might produce such ameliorating 308 
effects by counterbalancing the loss of CB1 receptors in selected brain areas, such as the BLA 309 
and the DH.  310 
In this latter area, we recently observed a dramatic deficit of glutamate neurotransmission in 311 
aged 3×Tg-AD mice. These lower levels of glutamate did not appear to be due to synaptic 312 
loss, as synaptophysin, a presynaptic vesicle marker of synaptic density, was not altered [13, 313 
31-34]. Within the hippocampus, CB1 receptors are highly expressed by GABAergic 314 
interneurons [35], where they negatively control GABA release on excitatory glutamatergic 315 
neurons. Therefore, it can be hypothesized that the reduced glutamatergic neurotransmission 316 
in this area might result from the reduced CB1 expression on GABA terminals and the 317 
consequent excessive GABA-mediated inhibition of glutamatergic neurons.  318 
Recently, CB1 was found to be expressed in mitochondria, and a novel role for CB1 receptors 319 
in the regulation of energy metabolism in the brain was proposed [36]. Aged 3×Tg-AD mice 320 
show severe mitochondrial impairment, as was previously shown by our group and by others 321 
[13, 37], and the hippocampus is the most severely affected area. This previous observation is 322 
in line with the current findings of reduced CB1 levels in DH of aged mutant mice. 323 
Apart from genetic factors, stress has also been suggested as a risk factor in developing AD 324 
and severe cognitive decline in AD patients. HPA axis dysregulation and elevated cortisol 325 
levels have been described in a substantial proportion of patients with AD [38-40]. Moreover, 326 
animal studies, including some performed on 3×Tg-AD mice, suggest some sort of interaction 327 
between corticosterone, dysregulation of the HPA axis and Aβ/tau pathology in AD [41, 42], 328 
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although the mechanisms underlying this interaction remain unknown. In particular, when 329 
corticosterone levels in 3×Tg-AD mice were evaluated, Green and colleagues found that basal 330 
corticosterone levels were unchanged until 9 months of age compared to aged matched non 331 
transgenic mice. After 9 months of age, corticosterone levels were significantly elevated in 332 
3×Tg-AD mice compared to age-matched non transgenic mice [42].  Although corticosterone 333 
levels were normal at early age, these mice showed activated HPA axis in 3-4-month-old 334 
3×Tg-AD.  At this age increased mRNA levels of mineralocorticoid receptor and 335 
glucocorticoids receptor were also observed in the hippocampus and PVN with no change in 336 
the amygdala, while the mRNA of corticotropin releasing hormone decreased in the PVN and 337 
increased in both the central nucleus of the amygdala and the bed nucleus of the stria 338 
terminalis [43].  339 
There is evidence that the ECS regulates the HPA axis by negatively modulating its activation 340 
induced by the exposure to stress [44-46]. Among other areas, CB1 receptors expressed in DH 341 
and BLA seem to be involved in negative feedback of glucocorticoids in these brain regions 342 
[47]. As a consequence, CB1 receptor blockade with the antagonist, SR141716, results in 343 
activation of the HPA axis as measured by an increase in plasma corticosterone levels in 344 
rodents [44]. Apart from dysregulated HPA axis, increased emotionality and depressive like 345 
behavior are reported in these mice [48]. We have observed depressive like behavior in these 346 
mice when subjected to a forced swimming and tail suspension test (unpublished data). 347 
Moreover, these mice are reported to show symptoms of anxiety and fear associated with 348 
spatial memory deficits. Authors proposed a deleterious role of intraneuronal Aβ on 349 
amygdala-dependent emotional responses [49]. A similar behavioral phenotype was observed 350 
in CB1-knockout mice (CB1-/-), which show also increased circulating levels of 351 
adrenocorticotropic hormone [46], corticosterone [50, 51], anxiety like and fear responses 352 
[52-54] as well as depressive like behavior [55, 56]. Our result might suggest that the 353 
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decreased CB1 like immunoreactivity found in DH and BLA in 3×Tg-AD mice could play a 354 
role in the hippocampus-related memory deficits and amygdala-related behavioural 355 
alterations.  356 
Interestingly, a recent study by Stumm et al, showed that the lack of CB1 receptors in CB1-/- 357 
mice over-expressing APP23 can result in reduction of amyloid plaque load, reduced in situ 358 
inflammation and impaired learning and memory in aged mice [34]. We propose that lowered 359 
CB1 receptor expression might contribute to the cognitive impairments and dysregulated 360 
HPA axis found in 3×Tg-AD mice. 361 
 Overall our results show that 3×Tg-AD do not have inborn altered CB1 mRNA and protein 362 
expression, as they did not show any alteration at 2 months of age when their phenotype is 363 
still normal. The altered CB1 mRNA/protein levels appear, rather, to be age-and/or 364 
pathology-dependent, thus supporting the idea of a critical role of the ECS in AD and its 365 
possible impact as novel pharmacological target. How AD pathology exactly affects CB1 366 
receptors and whether CB1 receptors and AD pathology are directly or indirectly linked needs 367 
to be further explored. 368 
369 
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Table 1. Summary of age related molecular and behavioral changes in 3×Tg-AD mice 553 
Age of 
3×Tg-AD 
mice 
CB1 receptor Molecular and behavioral observation Ref 
2 months 
mRNA and protein 
unchanged 
-no Aβ and tau pathology 
-cognitively unimpaired  
[9] 
4 months - 
-intraneuronal Aβ in hippocampus 
and amygdala 
-cognitively impaired 
-activated central HPA axis 
-normal corticosterone levels 
-altered mRNA levels of corticoid 
receptors and CRH 
[9, 42, 43, 57] 
6 months 
Increased mRNA in 
PFC, DH, BLA 
Decreased in mRNA 
in VH 
Protein unchanged 
-extracellular Aβ in neocortex  
-intraneuronal buildup in 
hippocampus, amygdala and cortex 
-impaired LTP 
-synaptic dysfunction 
[9, 14] 
9 months - -increased corticosterone levels [42] 
12 months 
Increased mRNA in 
PFC, PrL, DH, BLA 
Decreased mRNA in 
VH 
Decreased protein in 
DH and BLA 
Protein unchanged in 
PFC, PrL and VH 
extracellular Aβ deposits is evident 
in frontal cortex, amygdala, DH and 
VH 
-Tau pathology evident in 
hippocampus 
[9, 14] 
18 months - 
- deficits in glutamate 
neurotransmission and mitochondrial 
functions in prefrontal cortex and 
hippocampus 
- emotionality and depressive like 
behavior  
[13, 48] 
LTP, long-term potentiation; HPA, hypothalamic-pituitary-adrenal; CRH, corticotropin-554 
releasing hormone   555 
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Figure legends 556 
Fig.1. CB1 mRNA distribution pattern in Non-Tg and 3xTg-AD mice. (A) Representative 557 
micrographs of coronal sections from mouse brain showing distribution of CB1 mRNA 558 
scanned from autoradiographic film exposed for 3 days. The dashed lines indicate the brain 559 
regions where the optical density was measured. (B-F) CB1 mRNA expression levels in Non-560 
Tg (open bars) and 3xTg-AD mice (black bars) at 2, 6 and 12 months (2M, 6M, 12M, 561 
respectively) of age in PFC (B), PrL (C), DH (D), VH (E) and BLA (F). The data are 562 
expressed as means ± SEM * p < 0.05 vs Non-Tg and °p < 0.05 (n = 5 per group). 563 
 564 
Fig.2. CB1 protein distribution pattern in Non-Tg and 3xTg-AD mice. (A) Representative 565 
microphotographs of brain coronal sections showing CB1 immunostaining in the selected 566 
brain areas. The dashed lines indicate the brain regions where the optical density was 567 
measured. (B-F) CB1 protein expression levels in Non-Tg (open bars) and 3xTg-AD mice 568 
(black bars) at 2, 6 and 12 months (2M, 6M, 12M, respectively) in PFC (B), PrL (C), DH (D), 569 
VH (E) and BLA (F). The data are expressed as means ± SEM * p< 0.05 vs Non-Tg and 570 
°p<0.05 (n = 3 per group). 571 
 572 
Fig.3. CB1 protein expression by immunofluorescence staining in 12 months old 3xTg-AD 573 
mice. (A, B) Representative microphotographs of brain coronal sections showing nuclear 574 
staining with Hoechst (blue) and CB1 immunofluorescence staining (red) in the DH (A) and 575 
BLA (B) without or with CB1 antiserum incubation step. (C, D) CB1 protein expression 576 
levels measured in the DH (C) and in the BLA (D) of 12 month-old Non-Tg (open bars) and 577 
3xTg-AD mice (black bars). (E, F) Representative photographs for CB1 protein (red), Aβ 578 
protein (green) and nuclear staining with Hoechst (blue) in DH (E) and BLA (F). (G, H) 579 
Scatterplot of Aβ protein levels vs CB1 protein levels showing an inverse correlationship 580 
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(Pearson test) in both the DH (G, ρ= -0.7599, p<0.0001) and the BLA (H, ρ= -0.5052, 581 
p<0.001) The data are expressed as means ± SEM * p < 0.05 vs Non-Tg (n = 3 per group). 582 
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